---
title: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile
  in patients with autoimmune and cholestatic liver disease
date: '2024-01-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38268921/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240125170715&v=2.18.0
source: heidelberg[Affiliation]
description: 'INTRODUCTION: Immune checkpoint inhibitors (ICI) have revolutionized
  the treatment of many malignancies in recent years. However, immune-related adverse
  events (irAE) are a frequent concern in clinical practice. The safety profile of
  ICI for the treatment of malignancies in patients diagnosed with autoimmune and
  cholestatic liver disease (AILD) remains unclear. Due to this uncertainty, these
  patients were excluded from ICI clinical trials and ICI are withheld from this patient
  group. In ...'
disable_comments: true
---
INTRODUCTION: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune-related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the treatment of malignancies in patients diagnosed with autoimmune and cholestatic liver disease (AILD) remains unclear. Due to this uncertainty, these patients were excluded from ICI clinical trials and ICI are withheld from this patient group. In ...